Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Carmustine MeSH Descriptor Data 2025


MeSH Heading
Carmustine
Tree Number(s)
D02.065.950.594.247
D02.654.692.247
Unique ID
D002330
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D002330
Scope Note
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Entry Term(s)
1,3-Bis(2-Chloroethyl)-1-Nitrosourea
BCNU
BiCNU
FIVB
N,N'-Bis(2-Chloroethyl)-N-Nitrosourea
Nitrumon
Pharm Action
Antineoplastic Agents, Alkylating
Registry Numbers
U68WG3173Y
0
Related Numbers
154-93-8
CAS Type 1 Name
Urea, N,N'-bis(2-chloroethyl)-N-nitroso-
Previous Indexing
Alkylating Agents (1966-1971)
Nitroso Compounds (1966-1971)
Urea (1966-1971)
Public MeSH Note
73
History Note
73(72)
Date Established
1973/01/01
Date of Entry
1999/01/01
Revision Date
2020/05/27
Carmustine Preferred
Nitrumon Narrower
BiCNU Narrower
page delivered in 0.146s